General Information of Drug Metabolite (DM) (ID: DM000317)
DM Name
Glutamate
Synonyms
L-glutamic acid|GLUTAMIC ACID|56-86-0|L-glutamate|(2S)-2-Aminopentanedioic acid|(S)-2-Aminopentanedioic acid|Glutamidex|Glutaminol|H-Glu-OH|glutacid|Aciglut|glutaminic acid|L-Glutaminic acid|Glutamicol|Glutaton|(S)-Glutamic acid|Glusate|L-glu|L-(+)-glutamic acid|D-Glutamiensuur|alpha-aminoglutaric acid|Glutamic acid, L-|Acidum glutamicum|(S)-(+)-Glutamic acid|Acide glutamique|2-Aminoglutaric acid|Acidum glutaminicum|L-2-Aminoglutaric acid|1-Aminopropane-1,3-dicarboxylic acid|25513-46-6|Acido glutamico|FEMA No. 3285|L-alpha-Aminoglutaric acid|Glutamic acid (H-3)|Glutamate, L-|alpha-Glutamic acid|glut|glutamate|Glutamic acid (VAN)|a-Glutamic acid|L-Glutaminsaeure|Glutamic acid, (S)-|Glutaminic acid (VAN)|CCRIS 7314|L-Acido glutamico|Pentanedioic acid, 2-amino-, (S)-|glu|a-Aminoglutaric acid|Glutamic Acid [USAN:INN]|AI3-18472|L-a-Aminoglutaric acid|Acide glutamique [INN-French]|Acido glutamico [INN-Spanish]|Acidum glutamicum [INN-Latin]|EPA Pesticide Chemical Code 374350|NSC 143503|alpha-Aminoglutaric acid (VAN)|Glutamic Acid (L-glutamic acid)|2-Aminopentanedioic acid, (S)-|aminoglutaric acid|EINECS 200-293-7|L-2-amino-pentanedioic acid|UNII-3KX376GY7L|3KX376GY7L|INS NO.620|DTXSID5020659|CHEBI:16015|Gamma-L-Glutamic Acid|INS-620|L-Glutamic acid (9CI)|C5H9NO4|NSC-143503|L(+)-Glutamic acid|E620|Glutamic acid, L-, peptides|DTXCID30659|HSDB 490|E 620|E-620|EC 200-293-7|Sodium Glutamate (L-glutamic Acid)|NCGC00024502-03|L-Glutamic acid (JAN)|(S)-2-AMINO-1,5-PENTANEDIOIC ACID|L-Glutamic acid-13C5|L-GLUTAMIC ACID [JAN]|Acido glutamico (INN-Spanish)|Acidum glutamicum (INN-Latin)|(2S)-2-aminopentanedioate|l glutamic acid|GLUTAMIC ACID (EP MONOGRAPH)|GLUTAMIC ACID [EP MONOGRAPH]|.alpha.-Glutamic acid|ALANINE IMPURITY B (EP IMPURITY)|ALANINE IMPURITY B [EP IMPURITY]|6899-05-4|glt|2-Amino-pentanedioic acid|LYSINE ACETATE IMPURITY B (EP IMPURITY)|LYSINE ACETATE IMPURITY B [EP IMPURITY]|1-amino-propane-1,3-dicarboxylic acid|GLUTAMIC ACID [USAN]|55443-55-5|MFCD00002634|aminoglutarate|Gulutamine|alpha-Glutamate|a-Glutamate|L-gluatmate|a-Aminoglutarate|L-glutamic-acid|NSC143503|L-Glutamic adid|2-Aminoglutarate|Glutamate, L|1ftj|1xff|(S)-glutamate|Glutamic acid, L|L-a-Aminoglutarate|alpha-Aminoglutarate|Gulutamine (USP)|(L)-glutamic acid|H-Glu|L-Glutamic,(S)|L-(+)-Glutamate|L-alpha-Aminoglutarate|Glutamic acid (USP)|Tocris-0218|[3h]-l-glutamic acid|1ii5|Polyglutamic acid(PGA)|(+)-L-Glutamic acid|(S)-(+)-Glutamate|(S)-Glu|L-[14C(U)]glutamate|(S)-2-Aminopentanedioate|Biomol-NT_000170|D00ENY|GLUTAMIC ACID [MI]|L-Glutamic acid (JP17)|SCHEMBL2202|GLUTAMIC ACID [INN]|L-Glutamic acid, 98.5%|Lopac0_000529|S)-2-Aminopentanedioic acid|GLUTAMIC ACID [INCI]|GLUTAMIC ACID [VANDF]|L-GLUTAMIC ACID [FCC]|BPBio1_001132|CHEMBL575060|GTPL1369|GLUTAMIC ACID [USP-RS]|GLUTAMIC ACID [WHO-DD]|L-GLUTAMIC ACID [FHFI]|L-Glutamic acid, 99%, FCC|BDBM17657|CHEBI:53374|Glutamic acid, L-(7CI,8CI)|1-Aminopropane-1,3-dicarboxylate|(C5-H9-N-O4)x-|Glutamic acid, L- (7CI,8CI)|L (+)-glutamic acid, alpha-form|1-amino-propane-1,3-dicarboxylate|138-16-9|L-Glutamic acid, non-animal source|Pentanedioic acid, 2-amino-, (S)|Tox21_113053|HB0383|HSCI1_000269|PDSP1_000128|PDSP1_001539|PDSP2_000127|PDSP2_001523|s6266|AKOS006238837|AKOS015854087|AM81690|CCG-204619|DB00142|LS-2330|SDCCGSBI-0050512.P002|CAS-56-86-0|NCGC00024502-01|NCGC00024502-02|NCGC00024502-04|NCGC00024502-07|(2S)-2-aminopentanedioic acid;H-Glu-OH|AC-11294|DS-13284|HY-14608|LS-71885|(S)-1-Aminopropane-1,3-dicarboxylic acid|(S)-1-Aminopropane-1,3-dicarboxylic acid|CS-0003473|G0059|EN300-52632|L-Glutamic acid, BioUltra, >=99.5% (NT)|L-Glutamic acid, tested according to Ph.Eur.|C00025|D00007|L-Glutamic acid, NIST(R)RM 8573, USGS40|M02979|M03872|Glutamic acid, L-; ((S)-(+)-Glutamic acid)|L-Glutamic acid, JIS special grade, >=99.0%|L-Glutamic acid, NIST(R) RM 8574, USGS41|A831210|Glutamic acid, L-; ((S)-(+)-Glutamic acid)|SR-01000597730|J-502415|L-Glutamic acid, ReagentPlus(R), >=99% (HPLC)|L-Glutamic acid, Vetec(TM) reagent grade, >=99%|SR-01000597730-1|L-Glutamic acid, >=99%, FCC, natural sourced, FG|Q26995161|F8889-8668|Z756440052|27322E29-9696-49C1-B541-86BEF72DE2F3|Glutamic acid, European Pharmacopoeia (EP) Reference Standard|L-Glutamic acid, certified reference material, TraceCERT(R)|Glutamic acid, United States Pharmacopeia (USP) Reference Standard|L-Glutamic acid, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-100.5%
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 147.13 Topological Polar Surface Area 101
Heavy Atom Count 10 Rotatable Bond Count 4
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
PubChem CID
33032
Complexity
145
Formula
C5H9NO4
Canonical SMILES
C(CC(=O)O)C(C(=O)O)N
InChI
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
InChIKey
WHUUTDBJXJRKMK-VKHMYHEASA-N
IUPAC name
(2S)-2-aminopentanedioic acid
Toxicity Properties of This DM
Documented Toxicity Properties
Toxicity Class Unreported
Predicted Toxicity Properties
Physical and chemical properties LogP

The log of the n-octanol/water distribution coefficient.

LogP possess a leading position with considerable impact on both membrane permeability and hydrophobic binding to macromolecules. Therefore, LogP is widely used in drug discovery and development as an indicator of potential utility of a solute as a drug.

The predicted logP of a compound in the range from 0 to 3 log mol/L will be considered proper.

-3.725 TPSA

Topological polar surface area

In TPSA, PSA is estimated only from the syntype (topology) of atoms in the molecule, without considering the three-dimensional structure of the molecule, which is the origin of the name topological polar surface area.

The TPSA of a compound in the range from 0 to 140 will be considered proper, based on Veber rule.

100.62
Pfizer Rule: Accepted

Molecules with a high log P (>3) and low TPSA (<75) are likely to be toxic.

Pfizer infered the relationship between the physicochemical properties and toxicity of the drug from an animal tolerability (IVT) study dataset of 245 preclinical Pfizer compounds.Compounds with a high log P (>3) and low TPSA ( <75) are likely to be toxic.

(Bioorg Med Chem Lett. 18(17):4872-5. 2008)

Structural Characteristics ALARM NMR Rule

Molecules containing the reactivity-related thiol substructures are likely to be toxic.

The high-throughput screening (HTS) hit rate of reactive compounds was evaluated by NMR screening, X-ray crystallography and other biochemical and biophysical experiments, and then 75 thiol substructures for predicting reactivity were obtained by computational means for 2348 screening hit reactive compounds and 1156 reactive compounds obtained by La protein experiments.The molecule was matched to 75 reactivity-related substructures to obtain the information how many alarm groups the molecule contained and determine whether it was a thiol-reactive compound. Molecules with the thiol substructures are likely to be toxic.

(J Am Chem Soc. 127(1):217-24. 2005)

0 PAINS

Molecules containing the reactive substructures are likely to be toxic.

Pan Assay Interference Compounds (PAINS) is one of the most famous frequent hitters filters, which comprises 480 substructures derived from the analysis of FHs determined by six target-based HTS assay. By application of these filters, it is easier to screen false positive hits and to flag suspicious compounds in screening databases. One of the most authoritative medicine magazines Journal of Medicinal Chemistry even requires authors to provide the screening results with the PAINS alerts of active compounds when submitting manuscripts.

(J Med Chem. 45(1):137-42. 2002)

0
BMS Rule

Molecules containing the reactivity-related substructures are likely to be toxic.

BMS's primary HTS data over the past 12 years was evaluated and analyzed to determine the correlation of a group of compound functional groups with Promiscuity, defined as a drug that acts with multiple molecular targets and exhibits different pharmacological effects.

(J Chem Inf Model. 46(3):1060-8. 2006)

0 Chelator Rule

Molecules containing the substructures associated with metalloprotease targeting are likely to be toxic.

The chelate substructure fragment library (eCFL) for targeting metalloproteinases was prepared and its effectiveness in screening metalloproteinase inhibitors was verified by analysis and fluorescence-based assay experiments, and 55 substructures associated with metalloprotease targeting were finally determined as alert structures.

(ChemMedChem. 5(2):195-9. 2010)

0
Genotoxic Carcinogenicity Rule

Molecules containing the Genotoxic substructures are likely to be carcinogenic.

By constructing a molecular structure dataset containing the corresponding Ames test data (mutagens and non-mutagens). The substructure of the dataset is searched, and then the toxic substructure obtained by using chemical and mechanical knowledge and statistical criteria is derived, and the new toxic substructure is obtained and approved, and finally the reliability of the verification set is verified. Molecules containing these substructures may cause carcinogenicity or mutagenicity through genotoxic mechanisms.There are 117 substructures in this endpoint.

(J Med Chem. 48(1):312-20. 2005)

0 Non-genotoxic Carcinogenicity Rule

Molecules containing the NonGenotoxic substructures are likely to be carcinogenic.

Through the analysis and verification of the existing molecular library or the molecular library mined by data, the list of non-gene carcinogenic substructures (SA) is obtained according to the computerized data mining analysis, and finally the reliability of the substructure is verified. Molecules containing these substructures may cause carcinogenicity through nongenotoxic mechanisms. There are 23 substructures in this endpoint.

(Mutat Res. 659(3):248-61. 2008)

0
Toxicity Model Prediction hERG Blockers

The possibility of causing cardiotoxicity.

The human ether-a-go-go related gene. The During cardiac depolarization and repolarization, a voltage-gated potassium channel encoded by hERG plays a major role in the regulation of the exchange of cardiac action potential and resting potential. The hERG blockade may cause long QT syndrome (LQTS), arrhythmia, and Torsade de Pointes (TdP), which lead to palpitations, fainting, or even sudden death.So build a model by collecting a dataset to predict whether a compound is a hERG Blocker.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.011 (---) H-HT

The possibility of causing .hepatotoxicity.

The human hepatotoxicity. Drug induced liver injury is of great concern for patient safety and a major cause for drug withdrawal from the market. Adverse hepatic effects in clinical trials often lead to a late and costly termination of drug development programs.So build a model by collecting datasets to predict whether compounds will cause hepatotoxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.053 (---)
DILI

The possibility of causing liver injury.

Drug-induced liver injury (DILI) has become the most common safety problem of drug withdrawal from the market over the past 50 years.So build a model by collecting datasets to predict whether compounds will cause liver injury.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.013 (---) CAMES Toxicity

The possibility of causing mutagenicity.

The Ames test for mutagenicity. The mutagenic effect has a close relationship with the carcinogenicity, and it is the most widely used assay for testing the mutagenicity of compounds.So build a model by collecting datasets to predict whether compounds will cause mutagenicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.03 (---)
Carcinogencity

The possibility of causing Carcinogencity.

Among various toxicological endpoints of chemical substances, carcinogenicity is of great concern because of its serious effects on human health. The carcinogenic mechanism of chemicals may be due to their ability to damage the genome or disrupt cellular metabolic processes. Many approved drugs have been identified as carcinogens in humans or animals and have been withdrawn from the market.So build a model by collecting datasets to predict whether compounds will cause Carcinogencity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.061 (---) Respiratory Toxicity

The possibility of causing Respiratory Toxicity.

Among these safety issues, respiratory toxicity has become the main cause of drug withdrawal. Drug-induced respiratory toxicity is usually underdiagnosed because it may not have distinct early signs or symptoms in common medications and can occur with significant morbidity and mortality.Therefore, careful surveillance and treatment of respiratory toxicity is of great importance.So build a model by collecting datasets to predict whether compounds will cause Respiratory Toxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.056 (---)
Full List of Drug-Metabolizing Enzyme (DME) Related to This DM
DME(s) Producing This DM through Metabolism
DME Name DME ID Reactant Reaction Related Drug REF
Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (P5CDH) DMEN380 Unclear - Unclear Proline [1]
Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (P5CDH) DMEN380 Unclear - Unclear L-Proline [2] , [3] , [4] , [2]
Glutamate dehydrogenase 1 (GLUD1) DMEN032 Unclear - Unclear Ammonia [5]
Glutamate synthase [NADPH] large chain (gltB) DMEN202 Unclear - Unclear Oxoglutarate [6]
Glutamine synthetase (GLUL) DME0418 Unclear - Unclear L-glutamine [7] , [8] , [9]
L-glutamine amidohydrolase (GLS) DME0126 Unclear - Unclear L-glutamine [7] , [8] , [9]
NADP-specific glutamate dehydrogenase (gdhA) DMEN203 Unclear - Unclear Oxoglutarate [6]
Nonenzymatical (Non-ME) DMEN081 Conjugation - Amide Hydrolyation Thalidomide [10]
Pyroglutamase (OPLAH) DME0560 Unclear - Unclear ANW-43980 [11]
DME(s) Metabolizing This DM
DME Name DME ID Product Reaction Related Drug REF
aminotransferase (AT) DMEN729 Unclear - Unclear Arginine [12]
Glutamate decarboxylase (gadB) DME2101 Oxidation - Decarboxylation L-glutamine [13] , [14]
Glutamate decarboxylase (gadB) DME1344 Oxidation - Decarboxylation L-glutamine [13] , [14]
Glutamate decarboxylase (gadB) DME1344 Unclear - Unclear Arginine [12]
glutamate dehydrogenase (GLUD) DMEN728 Unclear - Unclear L-Proline [15]
glutamate dehydrogenase (GLUD) DMEN728 Unclear - Unclear Arginine [12]
Glutamine synthetase (GLUL) DME0418 Unclear - Unclear Arginine [12]
glutamine synthetase (GS) DMEN204 Unclear - Unclear Oxoglutarate [6]
Nonenzymatical (Non-ME) DMEN081 Conjugation - Amide Hydrolyation Thalidomide [10]
Full List of Drug(s) That Produce This DM By Metabolism
Thalidomide DR1572 Approved Breast cancer
L-glutamine DR0950 Approved Sickle-cell anaemia
Arginine DR5046 Approved Growth hormone deficiency
Ammonia DR0100 Approved Atherosclerosis
L-Proline DR5757 Approved Malnutrition
Gamma hydroxybutyric acid DR5442 Approved Narcolepsy
ANW-43980 DR2036 Phase 2 Parkinsonism
Oxoglutarate DR2059 Investigative Discovery agent
Proline DR1350 Investigative Discovery agent
References
1 Proline metabolism in cancer
2 L-proline dehydrogenases in hyperthermophilic archaea: distribution, function, structure, and application
3 Structural analysis of prolines and hydroxyprolines binding to the l-glutamate--semialdehyde dehydrogenase active site of bifunctional proline utilization A
4 Structural basis for the stereospecific inhibition of the dual proline/hydroxyproline catabolic enzyme ALDH4A1 by trans-4-hydroxy-L-proline
5 Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases J Hepatol. 2016 Apr;64(4):860-71. doi: 10.1016/j.jhep.2015.11.018.
6 The Emergence of 2-Oxoglutarate as a Master Regulator Metabolite
7 Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation Nutrients. 2018 Oct 23;10(11):1564. doi: 10.3390/nu10111564.
8 The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications Amino Acids. 2016 Sep;48(9):2067-80. doi: 10.1007/s00726-016-2254-8.
9 Inhibitors of glucosamine-6-phosphate synthase as potential antimicrobials or antidiabetics - synthesis and properties. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1928-1956. doi: 10.1080/14756366.2022.2096018.
10 Thalidomide metabolism and hydrolysis: mechanisms and implications
11 Sexual dimorphism in glutathione metabolism and glutathione-dependent responses
12 Arginine Metabolism Revisited
13 Glutamate decarboxylase-dependent acid resistance in orally acquired bacteria: function, distribution and biomedical implications of the gadBC operon. Mol Microbiol. 2012 Nov;86(4):770-86.
14 The delta subunit of the GABA(A) receptor is necessary for the GPT2-promoted breast cancer metastasis. Theranostics. 2023 Feb 21;13(4):1355-1369. doi: 10.7150/thno.80544.
15 Proline Metabolism in Cell Regulation and Cancer Biology: Recent Advances and Hypotheses

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.